Arcutis Biotherapeutics, Inc. (ARQT) Stock Score, Valuation & Financial Research
Arcutis Biotherapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 30/100.
Quick answer for ARQT
Arcutis Biotherapeutics, Inc. currently has a Wall Street Score of 30/100. The stored market price is $23.89. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Arcutis Biotherapeutics, Inc. does
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis
ARQT financial snapshot
- Wall Street Score:
- 30/100
- Current price:
- $23.89
- Market capitalization:
- $2.99B
- Revenue:
- $464.0M
- Net income:
- $28.5M
- Free cash flow:
- $-6.3M
- Cash:
- $34.1M
- Total debt:
- $114.1M
- EPS:
- 0.22
- P/E ratio:
- 108.2x
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 43/100
What stands out
- Reported year-over-year revenue growth is +0.2%.
- Free cash flow is $-6.3M, showing cash burn in the current stored period.
- The balance sheet shows $34.1M of cash versus $114.1M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ARQT
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.